CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Project Number||pCODR 10227|
|Generic Name||Polatuzumab Vedotin|
|Indication||Diffuse Large B-Cell Lymphoma (DLBCL)|
|Funding Request||Polatuzumab vedotin, in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, who are not eligible for autologous stem cell transplant and have received at least one prior therapy.|
|Review Status||Under Review|
|Pre Noc Submission||No|
|Manufacturer||Hoffmann-La Roche Limited|
|Sponsor||Hoffmann-La Roche Limited|
|Submission Date||September 29, 2020|
|Submission Deemed Complete||October 16, 2020|
|Submission Type||New Drug|
|Stakeholder Input Deadline ‡||October 14, 2020|
|Check-point meeting||December 3, 2020|
|pERC Meeting (target date)|
|Initial Recommendation Issued (target date)|
|Feedback Deadline (target date) ‡|
|pERC Reconsideration Meeting (target date)|
|Final Recommendation Issued (target date)|
|Notification to Implement Issued|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.